Sheeza Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sheeza Ali has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Kannan Subbaram
School of Medicine, The Maldives National University, Male’, Maldives
8 shared publications - Razana Faiz
School of Medicine, The Maldives National University, Male’, Maldives
6 shared publications - Queen Alice Arul
All India Institute of Medical Sciences, Kalyani, India
4 shared publications - Aminath Efa Ibrahim
School of Medicine, The Maldives National University, Male’, Maldives
2 shared publications - Fathimath Ina Shareef
School of Medicine, The Maldives National University, Male’, Maldives
2 shared publications - Ahmed Naueen Nazim
School of Medicine, The Maldives National University, Male’, Maldives
1 shared publication
Latest Publications
- 1 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Gut microbiome influences the efficacy of neuropsychiatric drugs
Gut microbiome influences the efficacy of neuropsychiatric drugs
- 1 June 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Gut microbiome influences the efficacy of neuropsychiatric drugs
Gut microbiome influences the efficacy of neuropsychiatric drugs
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 216-217
Exosome Derived Micro RNA: A Promising Modality in the Treatment of Spinal Cord Injury and Peripheral Neuropathy
Exosome Derived Micro RNA: A Promising Modality in the Treatment of Spinal Cord Injury and Peripheral Neuropathy
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 216-217
Exosome Derived Micro RNA: A Promising Modality in the Treatment of Spinal Cord Injury and Peripheral Neuropathy
Exosome Derived Micro RNA: A Promising Modality in the Treatment of Spinal Cord Injury and Peripheral Neuropathy
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 213-215
Long Acting and Highly Effective Pre-Exposure Prophylaxis (Prep) Using Injectable Lenacapavir (LEN) for HIV Infection
Long Acting and Highly Effective Pre-Exposure Prophylaxis (Prep) Using Injectable Lenacapavir (LEN) for HIV Infection
- 10 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 213-215
Long Acting and Highly Effective Pre-Exposure Prophylaxis (Prep) Using Injectable Lenacapavir (LEN) for HIV Infection
Long Acting and Highly Effective Pre-Exposure Prophylaxis (Prep) Using Injectable Lenacapavir (LEN) for HIV Infection
- Open Access
- 11 October 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (4) , 686-688
Oncolytic Viruses: Promising Future in Cancer Treatment
Oncolytic Viruses: Promising Future in Cancer Treatment
- 11 October 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (4) , 686-688
Open AccessOncolytic Viruses: Promising Future in Cancer Treatment
Oncolytic Viruses: Promising Future in Cancer Treatment
- Open Access
- 31 August 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (3) , 479-481
Novel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system
Novel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system
- 31 August 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (3) , 479-481
Open AccessNovel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system
Novel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system
- Open Access
- 5 June 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (2) , 228-229
Bacteria associated with prostate cancer progression and new strategy in the treatment
Bacteria Associated with Prostate Cancer Progression and New Strategy in the Treatment
- 5 June 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (2) , 228-229
Open AccessBacteria associated with prostate cancer progression and new strategy in the treatment
Bacteria Associated with Prostate Cancer Progression and New Strategy in the Treatment
- Open Access
- 23 May 2020
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 14 (suppl 1) , 757-763
Molecular Characterization and Amino Acid Homology of Nucleocapsid (N) Protein in SARS-CoV-1, SARS-CoV-2, MERS-CoV, and Bat Coronavirus
Coronavirus disease – 2019 (COVID-19) pandemic, due to severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2), is posing a severe bio threat to the entire world. Nucleocapsids of SARS-CoV-2 and the related viruses were studied for gene and amino acid sequence homologies. In this study, we established similarities and differences in nucleocapsids in SARS-CoV-2, severe acute respiratory syndrome – coronavirus-1 (SARS-CoV-1), bat coronavirus (bat-CoV) and Middle East respiratory syndrome – coronavirus (MERS-CoV). We conducted a detailed analysis of the nucleocapsid protein amino acid and gene sequence encoding it, found in various coronavirus strains. After thoroughly screening the different nucleocapsids, we observed a close molecular homology between SARS-CoV-1 and SARS-CoV-2. More than 95% sequence similarity was observed between the two SARS-CoV strains. Bat-CoV and SARS-CoV-2 showed 92% sequence similarity. MERS-CoV and SARS-CoV-2 nucleocapsid analysis indicated only 65% identity. Molecular characterization of nucleocapsids from various coronaviruses revealed that SARS-CoV 2 is more related to SARS-CoV 1 and bat-CoV. SARS-CoV 2 exhibited less resemblance with MERS-CoV. SARS-CoV 2 showed less similarity to MERS-CoV. Thus, either SARS-CoV-1 or bat-CoV may be the source of SARS-CoV-2 evolution. Moreover, the existing differences in nucleocapsid molecular structures in SARS-CoV-2 make this virus more virulent and highly infectious, which means that the non-identical SARS-CoV-2 genes (which are absent in SARS-CoV-1 and bat-CoV) are responsible for COVID-19 severity. We observed that SARS-CoV-2 nucleocapsid from different locations varied in amino acid sequences. This revealed that there are many SARS-CoV-2 subtypes/subsets currently circulating globally. This study will help to develop antiviral vaccine and drugs, study viral replication and immunopathogenesis, and synthesize monoclonal antibodies that can be used for precise COVID-19 diagnosis, without false-positive/false-negative results.
- 23 May 2020
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 14 (suppl 1) , 757-763
Open AccessMolecular Characterization and Amino Acid Homology of Nucleocapsid (N) Protein in SARS-CoV-1, SARS-CoV-2, MERS-CoV, and Bat Coronavirus
Coronavirus disease – 2019 (COVID-19) pandemic, due to severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2), is posing a severe bio threat to the entire world. Nucleocapsids of SARS-CoV-2 and the related viruses were studied for gene and amino acid sequence homologies. In this study, we established similarities and differences in nucleocapsids in SARS-CoV-2, severe acute respiratory syndrome – coronavirus-1 (SARS-CoV-1), bat coronavirus (bat-CoV) and Middle East respiratory syndrome – coronavirus (MERS-CoV). We conducted a detailed analysis of the nucleocapsid protein amino acid and gene sequence encoding it, found in various coronavirus strains. After thoroughly screening the different nucleocapsids, we observed a close molecular homology between SARS-CoV-1 and SARS-CoV-2. More than 95% sequence similarity was observed between the two SARS-CoV strains. Bat-CoV and SARS-CoV-2 showed 92% sequence similarity. MERS-CoV and SARS-CoV-2 nucleocapsid analysis indicated only 65% identity. Molecular characterization of nucleocapsids from various coronaviruses revealed that SARS-CoV 2 is more related to SARS-CoV 1 and bat-CoV. SARS-CoV 2 exhibited less resemblance with MERS-CoV. SARS-CoV 2 showed less similarity to MERS-CoV. Thus, either SARS-CoV-1 or bat-CoV may be the source of SARS-CoV-2 evolution. Moreover, the existing differences in nucleocapsid molecular structures in SARS-CoV-2 make this virus more virulent and highly infectious, which means that the non-identical SARS-CoV-2 genes (which are absent in SARS-CoV-1 and bat-CoV) are responsible for COVID-19 severity. We observed that SARS-CoV-2 nucleocapsid from different locations varied in amino acid sequences. This revealed that there are many SARS-CoV-2 subtypes/subsets currently circulating globally. This study will help to develop antiviral vaccine and drugs, study viral replication and immunopathogenesis, and synthesize monoclonal antibodies that can be used for precise COVID-19 diagnosis, without false-positive/false-negative results.